Degrader of cancer protein IDO1 prevents cancer immune suppression by cancer and offers promising strategy to support ...

Scientists have demonstrated a dependable method to generate large numbers of helper T cells from stem cells, removing a long-standing obstacle that has limited immune-based cancer treatments. The ...

The Global Mantle Cell Lymphoma Market offers significant growth potential driven by an aging population increasing cancer prevalence and the success of targeted oral drugs and immunotherapies. Rapid ...

Inovio Pharmaceuticals faces an October 30 PDUFA date for INO-3107 with high regulatory risk and only a 5-7 month cash runway. Read why INO stock is a hold.

Biomarker testing is crucial for personalized oncology care, aiding in risk stratification and treatment decisions, but faces challenges in uptake and education. Multistakeholder partnerships and ...

T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells.

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an ...

The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...

How do immune cells strike a balance, unleashing rapid attacks against pathogens or cancer, while avoiding damage to healthy ...

Researchers found an antibody that seems to play a role in people with better lung cancer prognoses, but turning it into a ...

Chemotherapy reshapes gut bacteria in ways that send powerful signals throughout the body. These signals reprogram immune cells, making organs like the liver more resistant to metastatic cancer.